Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia

[1]  George Davey Smith,et al.  Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference , 2018, Nature Communications.

[2]  Andrey Ziyatdinov,et al.  lme4qtl: linear mixed models with flexible covariance structure for genetic studies of related individuals , 2017, bioRxiv.

[3]  S. Humphries,et al.  Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK , 2017, European heart journal.

[4]  Bradley P. Coe,et al.  Targeted sequencing identifies 91 neurodevelopmental disorder risk genes with autism and developmental disability biases , 2017, Nature Genetics.

[5]  G. Watts,et al.  Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. , 2017, Journal of clinical lipidology.

[6]  Marylyn D. Ritchie,et al.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system , 2016, Science.

[7]  S. Humphries,et al.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update , 2016, Journal of Medical Genetics.

[8]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[9]  L. Pérez de Isla,et al.  Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study) , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[10]  D. Lloyd‐Jones,et al.  Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype , 2016, Circulation.

[11]  Silja Martikainen,et al.  Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. , 2016, Cell metabolism.

[12]  J. Danesh,et al.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. , 2016, Journal of the American College of Cardiology.

[13]  G. Watts,et al.  Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. , 2016, European heart journal.

[14]  K. Retterstøl,et al.  Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. , 2016, European heart journal.

[15]  Emily C. O'Brien,et al.  Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry , 2016, Circulation. Cardiovascular genetics.

[16]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[17]  Matthew K Ito,et al.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[18]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[19]  R. Mägi,et al.  Cohort Profile Cohort Profile : Estonian Biobank of the Estonian Genome Center , University of Tartu , 2015 .

[20]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[21]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[22]  Evan E. Eichler,et al.  A Genotype-First Approach to Defining the Subtypes of a Complex Disease , 2014, Cell.

[23]  Jennifer G. Robinson,et al.  Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. , 2014, American journal of human genetics.

[24]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[27]  R. Fresa,et al.  Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. , 2013, Atherosclerosis.

[28]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[29]  J. Fajkus,et al.  Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia , 2010, BMC Medical Genetics.

[30]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[31]  K. Kulkarni,et al.  Cholesterol profile measurement by vertical auto profile method. , 2006, Clinics in laboratory medicine.

[32]  Richard A. Kronmal,et al.  Distribution of Coronary Artery Calcium by Race, Gender, and Age: Results from the Multi-Ethnic Study of Atherosclerosis (MESA) , 2005, Circulation.

[33]  F. Karpe,et al.  The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank , 2005, Diabetologia.

[34]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.

[35]  J. Kastelein,et al.  Advanced method for the identification of patients with inherited hypercholesterolemia. , 2004, Seminars in vascular medicine.

[36]  E. Sijbrands,et al.  Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands , 2001, The Lancet.

[37]  J. Borén,et al.  Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. , 1998, The Journal of clinical investigation.

[38]  J. Segrest,et al.  Quantification of cholesterol in all lipoprotein classes by the VAP-II method. , 1994, Journal of lipid research.

[39]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[40]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[41]  T. Farag,et al.  Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.